Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 122 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Cómo prepararse para su exploración por TEP-TC April 1, 2021 Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed... June 10, 2022 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... September 10, 2022 Load more HOT NEWS Study in India Could Make Immunotherapy More Affordable Worldwide Happy New Year From Our Team Five Questions with…Fred. Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma
